Fagron N.V.

Transaction in Own Shares • Aug 13, 2013

Waregem (Belgium) / Rotterdam (the Netherlands)¹ , 12 August 2013 – Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that during the period from 2 August to 12 August, it acquired 83,582 treasury shares on NYSE Euronext Brussels (through an intermediate, acting with a discretionary mandate).

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
2 August 2013	19,053	€ 21.5110	€ 21.20	€ 22.21	€ 409,849
5 August 2013	15,000	€ 21.8911	€ 21.65	€ 21.97	€ 328,367
6 August 2013	15,000	€ 21.8007	€ 21.48	€ 21.91	€ 327,011
7 August 2013	4,637	€ 21.5643	€ 21.33	€ 21.65	€ 99,994
8 August 2013	10,000	€ 21.8279	€ 21.44	€ 21.89	€ 218,279
9 August 2013	10,000	€ 21.8628	€ 21.77	€ 21.90	€ 218,628
12 August 2013	9,892	€ 21.4212	€ 21.19	€ 21.75	€ 211,899

In addition, during the period from 2 August to 12 August, Arseus acquired 166,418 treasury shares via various block trades.

Acquisition date	Block	Price	Amount
2 August 2013	10,000	€ 21.60	€ 216,000
5 August 2013	5,000	€ 21.88	€ 109,400
5 August 2013	26,418	€ 21.95	€ 579,875
5 August 2013	50,000	€ 21.95	€ 1,097,500
6 August 2013	50,000	€ 21.83	€ 1,091,500
6 August 2013	25,000	€ 21.84	€ 546,000

¹ This press release was sent out by Arseus NV and Arseus BV.

The Extraordinary Shareholders' Meeting held on 16 June 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.

Prior to the transactions, Arseus held 381,378 treasury shares. As a result of the acquisition of 250,000 treasury shares, Arseus now holds 631,378 treasury shares.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

For more information:

Constantijn van Rietschoten Director of Corporate Communications +31 88 33 11 222 (Office) +31 6 53 69 15 85 (Mobile) constantijn.van.rietschoten@arseus.com

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.

2/2